Published in Nephron Physiol on March 22, 2006
Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis (2009) 4.30
In vivo multiphoton imaging of mitochondrial structure and function during acute kidney injury. Kidney Int (2012) 1.21
Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J (2010) 1.18
Gender differences in kidney function. Pflugers Arch (2007) 1.14
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflugers Arch (2012) 0.93
Advances in biochemical screening for phaeochromocytoma using biogenic amines. Clin Biochem Rev (2009) 0.87
A human in vitro model that mimics the renal proximal tubule. Tissue Eng Part C Methods (2014) 0.79
Disposition kinetics of a dipeptide ester prodrug of acyclovir and its metabolites following intravenous and oral administrations in rat. Clin Res Regul Aff (2009) 0.78
Renal handling of amphotericin B and amphotericin B-deoxycholate and potential renal drug-drug interactions with selected antivirals. Antimicrob Agents Chemother (2014) 0.78
Adaptive response to increased bile acids: induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch (2007) 0.78
Mechanisms of chemical carcinogenesis in the kidneys. Int J Mol Sci (2013) 0.77
Mechanistic models describing active renal reabsorption and secretion: a simulation-based study. AAPS J (2012) 0.77
Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and L-lactate in rats. J Pharmacokinet Pharmacodyn (2015) 0.76
Drug-Induced Metabolic Acidosis. F1000Res (2015) 0.75
7. Drug-Induced Kidney Injury. EJIFCC (2009) 0.75
Antiviral drug-induced nephrotoxicity. Am J Kidney Dis (2005) 1.87
Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int (2004) 1.74
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem (2007) 1.72
Vaccination and chronic kidney disease. Nephrol Dial Transplant (2007) 1.63
Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant (2006) 1.61
Ear and kidney syndromes: molecular versus clinical approach. Kidney Int (2004) 1.59
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Renal safety of tenofovir in HIV treatment-experienced patients. AIDS (2004) 1.50
Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis (2007) 1.49
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant (2005) 1.49
Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation (2002) 1.47
L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol (2012) 1.44
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int (2004) 1.43
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol (2008) 1.43
Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant (2005) 1.40
Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant (2003) 1.40
Impact of inodilator drugs on echocardiographic assessments of left ventricular filling pressure in patients with decompensated end-stage heart failure*. Crit Care Med (2014) 1.39
Drug-induced Fanconi's syndrome. Am J Kidney Dis (2003) 1.38
Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs (2009) 1.26
Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis (2008) 1.25
Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med (2008) 1.24
Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology (2002) 1.19
Herbs and the kidney. Am J Kidney Dis (2004) 1.16
Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant (2006) 1.08
Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol (2013) 1.07
Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. Clin Pharmacol Ther (2002) 1.06
Abnormal blood pressure circadian rhythm: a target organ damage? Int J Cardiol (2006) 1.06
Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol (2009) 1.04
Post-colonoscopy appendicitis: case report and review of the literature. Am J Gastroenterol (2005) 1.04
Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. Eur J Radiol (2009) 1.03
Post-transplantation proteinuria and sirolimus. N Engl J Med (2005) 1.03
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Atazanavir crystal nephropathy. AIDS (2007) 1.02
Adefovir dipivoxil-induced acute tubular necrosis and Fanconi syndrome in a renal transplant patient. AIDS (2009) 1.01
Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol (2002) 1.01
Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit (2004) 1.00
A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics (2005) 0.99
Renal tubular transporters and antiviral drugs: an update. AIDS (2005) 0.99
Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology (2009) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol (2009) 0.97
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome? J Natl Cancer Inst (2007) 0.96
Viral load and HIV-associated nephropathy. N Engl J Med (2005) 0.96
Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer (2011) 0.96
Kidney diseases in HIV/HCV-co-infected patients. AIDS (2009) 0.95
Renal biopsy practice in France: results of a nationwide study. Nephrol Dial Transplant (2010) 0.93
Sunitinib malate. Cancer Chemother Pharmacol (2006) 0.92
Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol (2006) 0.92
Tubulointerstitial nephritis and uveitis syndrome (TINU): a step forward to understanding an elusive oculorenal syndrome. Nephrol Dial Transplant (2008) 0.92
Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence? AIDS (2010) 0.91
Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. Cancer (2014) 0.91
Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. Liver Int (2014) 0.90
Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis. Am J Med (2002) 0.90
Effect of catheter-lock solutions on catheter-related infection and inflammatory syndrome in hemodialysis patients: heparin versus citrate 46% versus heparin/gentamicin. Blood Purif (2010) 0.90
Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer (2009) 0.88
Eye and kidney: from clinical findings to genetic explanations. J Am Soc Nephrol (2003) 0.88
Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol (2009) 0.88
Fanconi syndrome associated with didanosine therapy. AIDS (2005) 0.88
Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure. Am Heart J (2003) 0.88
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Nephrol Dial Transplant (2006) 0.88
Macrocytosis due to treatment with sunitinib. N Engl J Med (2007) 0.87
Central venous stenosis as a complication of ipsilateral haemodialysis fistula and pacemaker. Nephrol Dial Transplant (2005) 0.87
Tubular transporters and clearance of adefovir. Eur J Pharmacol (2006) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
Immune reconstitution inflammatory syndrome and acute granulomatous interstitial nephritis. AIDS (2007) 0.85
Clinical review: use of vancomycin in haemodialysis patients. Crit Care (2002) 0.85
Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis (2007) 0.85
Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant (2003) 0.84
Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol (2005) 0.84
Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl (2009) 0.84
Antiretroviral nephrotoxicities. Semin Nephrol (2008) 0.84
[Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique]. Nephrol Ther (2008) 0.83